Illumina Agrees To Delay $8B Grail Deal During FTC Challenge
Illumina Inc. has agreed to delay closing its planned $8 billion acquisition of cancer detection firm Grail Inc. until as late as September while the Federal Trade Commission challenges the deal...To view the full article, register now.
Already a subscriber? Click here to view full article